Q3 2024 EPS Estimates for Repligen Co. Raised by Analyst (NASDAQ:RGEN)

Repligen Co. (NASDAQ:RGEN - Free Report) - Analysts at William Blair upped their Q3 2024 earnings per share estimates for shares of Repligen in a note issued to investors on Thursday, May 2nd. William Blair analyst M. Larew now anticipates that the biotechnology company will post earnings per share of $0.42 for the quarter, up from their prior estimate of $0.38. The consensus estimate for Repligen's current full-year earnings is $1.46 per share. William Blair also issued estimates for Repligen's Q4 2024 earnings at $0.47 EPS, FY2024 earnings at $1.46 EPS and FY2025 earnings at $2.24 EPS.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing analysts' consensus estimates of $0.29 by ($0.01). The firm had revenue of $151.31 million during the quarter, compared to analysts' expectations of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. The company's revenue for the quarter was down 17.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.64 EPS.

Several other analysts have also recently issued reports on the company. KeyCorp increased their price objective on Repligen from $210.00 to $220.00 and gave the company an "overweight" rating in a research note on Thursday, February 15th. JPMorgan Chase & Co. lowered their price objective on Repligen from $230.00 to $200.00 and set an "overweight" rating for the company in a research report on Thursday. Finally, Stifel Nicolaus raised their target price on shares of Repligen from $165.00 to $207.00 and gave the company a "buy" rating in a report on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $197.75.

Repligen Trading Up 0.6 %

NASDAQ RGEN traded up $0.99 on Monday, reaching $168.04. The stock had a trading volume of 458,055 shares, compared to its average volume of 540,167. Repligen has a 12-month low of $110.45 and a 12-month high of $211.13. The stock has a fifty day moving average price of $180.34 and a two-hundred day moving average price of $174.47. The firm has a market capitalization of $9.39 billion, a price-to-earnings ratio of 672.19, a P/E/G ratio of 5.58 and a beta of 1.03. The company has a quick ratio of 5.24, a current ratio of 6.35 and a debt-to-equity ratio of 0.26.

Hedge Funds Weigh In On Repligen

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in Repligen by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 5,078,294 shares of the biotechnology company's stock worth $913,077,000 after acquiring an additional 33,404 shares during the period. Artisan Partners Limited Partnership grew its holdings in Repligen by 11.3% in the 3rd quarter. Artisan Partners Limited Partnership now owns 1,556,873 shares of the biotechnology company's stock valued at $247,558,000 after buying an additional 157,807 shares during the period. Brown Capital Management LLC increased its stake in shares of Repligen by 5.8% during the 4th quarter. Brown Capital Management LLC now owns 1,525,064 shares of the biotechnology company's stock valued at $274,207,000 after acquiring an additional 83,416 shares during the last quarter. Wellington Management Group LLP grew its holdings in Repligen by 2.1% in the third quarter. Wellington Management Group LLP now owns 1,396,610 shares of the biotechnology company's stock valued at $222,075,000 after purchasing an additional 29,215 shares during the period. Finally, Bank of New York Mellon Corp grew its holdings in Repligen by 13.0% in the third quarter. Bank of New York Mellon Corp now owns 1,195,629 shares of the biotechnology company's stock valued at $190,117,000 after purchasing an additional 137,220 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.

Insider Transactions at Repligen

In other Repligen news, Director Karen A. Dawes sold 1,000 shares of the firm's stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total value of $193,350.00. Following the completion of the sale, the director now owns 87,367 shares of the company's stock, valued at $16,892,409.45. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, VP Ralf Kuriyel sold 3,517 shares of Repligen stock in a transaction on Monday, March 11th. The stock was sold at an average price of $193.73, for a total transaction of $681,348.41. Following the completion of the transaction, the vice president now owns 24,260 shares of the company's stock, valued at approximately $4,699,889.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Karen A. Dawes sold 1,000 shares of the business's stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total transaction of $193,350.00. Following the completion of the sale, the director now owns 87,367 shares in the company, valued at $16,892,409.45. The disclosure for this sale can be found here. In the last three months, insiders sold 25,597 shares of company stock valued at $5,039,532. Corporate insiders own 1.20% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.